KANOVSKY STEPHEN M 4
4 · NEOGENOMICS INC · Filed Jun 3, 2026
Research Summary
AI-generated summary of this filing
NeoGenomics (NEO) Director Stephen Kanovsky Exercises Options, Receives RSUs
What Happened
- Stephen M. Kanovsky, a director of NeoGenomics Inc. (NEO), exercised/converted a derivative and had restricted stock units (RSUs) released on 2026-06-01. The filing shows acquisition of 23,077 shares via exercise/conversion (exercise price $0.00) and the release/grant-acquisition of 11,069 and 15,970 shares (both derivative/RSU-related). There is also a corresponding reported disposition of 23,077 derivative shares at $0.00. In total the filing records 50,116 shares acquired and 23,077 derivative shares disposed, a net increase of 27,039 shares for the insider per this report. The filing lists $0.00 as the price on these transactions, so no cash payment is shown.
Key Details
- Transaction date: 2026-06-01 (reported on Form 4 filed 2026-06-03)
- Recorded transactions:
- Exercise/conversion (M): 23,077 shares acquired @ $0.00
- Exercise/conversion (M): 23,077 shares disposed @ $0.00 (derivative)
- Grant/award release (A): 11,069 shares acquired @ $0.00 (derivative; RSU release)
- Grant/award release (A): 15,970 shares acquired @ $0.00 (derivative; RSU release)
- Net change reported on this Form 4: +27,039 shares (50,116 acquired minus 23,077 disposed)
- Shares owned after the transactions: not stated in the provided filing summary
- Footnotes in the filing:
- F1: The reported acquisitions reflect the release of restricted stock units previously reported on a Form 4.
- F2: Once vested, the released shares of common stock are not subject to expiration.
- Filing timeliness: Form 4 filed 2 days after the transaction date (appears timely, not marked late)
Context
- Derivative explanation: The filing shows an exercise/conversion of a derivative instrument and the release of RSUs. When a derivative is exercised or RSUs vest, shares are typically issued to the insider; the $0.00 exercise/price here means the filing shows no cash paid for those reported shares. The separate disposition entry at $0.00 likely reflects an internal conversion/settlement reporting detail rather than an open-market sale for cash.
- For retail investors: awards and RSU releases are common forms of compensation and do not necessarily signal a buy/sell decision; purchases are generally more informative about insider sentiment. This report documents compensation-related issuance and a net increase in the director’s holdings per the filing.
Insider Transaction Report
Form 4
KANOVSKY STEPHEN M
Director
Transactions
- Exercise/Conversion
Common Stock
[F1]2026-06-01+23,077→ 75,421 total - Exercise/Conversion
Restricted Stock Unit
[F2]2026-06-01−23,077→ 0 totalExercise: $0.00From: 2026-06-01→ Common Stock (23,077 underlying) - Award
Stock Option (Right to Buy)
2026-06-01+11,069→ 11,069 totalExercise: $10.52From: 2027-06-01Exp: 2036-06-01→ Common Stock (11,069 underlying) - Award
Restricted Stock Unit
[F2]2026-06-01+15,970→ 15,970 totalExercise: $0.00From: 2027-06-01→ Common Stock (15,970 underlying)
Holdings
- 4,269
Stock Option (Right to Buy)
Exercise: $22.52From: 2020-06-06Exp: 2026-06-06→ Common Stock (4,269 underlying) - 3,448
Stock Option (Right to Buy)
Exercise: $28.54From: 2021-05-28Exp: 2027-05-28→ Common Stock (3,448 underlying) - 3,714
Stock Option (Right to Buy)
Exercise: $40.90From: 2022-06-02Exp: 2028-06-02→ Common Stock (3,714 underlying) - 13,882
Stock Option (Right to Buy)
Exercise: $8.10From: 2023-06-10Exp: 2029-06-10→ Common Stock (13,882 underlying) - 8,353
Stock Option (Right to Buy)
Exercise: $14.82From: 2024-08-10Exp: 2033-08-10→ Common Stock (8,353 underlying) - 8,672
Stock Option (Right to Buy)
Exercise: $13.71From: 2025-06-01Exp: 2034-06-01→ Common Stock (8,672 underlying) - 16,107
Stock Option (Right to Buy)
Exercise: $7.28From: 2026-06-01Exp: 2035-06-01→ Common Stock (16,107 underlying)
Footnotes (2)
- [F1]Reflects the release of restricted stock units that were previously reported on a Form 4.
- [F2]Once vested, the shares of common stock are not subject to expiration.
Signature
/s/ Ali Olivo, Attorney-in-Fact|2026-06-03